<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052298</url>
  </required_header>
  <id_info>
    <org_study_id>13013</org_study_id>
    <secondary_id>2008-006770-14</secondary_id>
    <nct_id>NCT01052298</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (GOLD I - II), Following Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of the study are to investigate the safety, tolerability and levels of
      ciprofloxacin in the lung after single and multiple inhalative administration to patients
      with mild to moderate COPD (stage I-II according to GOLD Criteria).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs: evaluated by heart rate, blood pressure, clinical laboratory</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram: evaluated by shape and time intervals</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function test evaluated by FEV1</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse oximetry by peripheral oxygen concentration</measure>
    <time_frame>Within 12 days after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of ciprofloxacin concentration in blood</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of ciprofloxacin concentration in urine</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of ciprofloxacin concentration in sputum</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of ciprofloxacin concentration in oral rinsing fluid</measure>
    <time_frame>Within 7 days after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Disease, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (Cipro inhale, BAYQ3939)</intervention_name>
    <description>32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (Cipro inhale, BAYQ3939)</intervention_name>
    <description>32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (Cipro inhale, BAYQ3939)</intervention_name>
    <description>48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with COPD (Stage I or II according to the GOLD Classification), 35
             years of age or older

          -  Airway obstruction with a post-bronchodilator Forced Expiratory Volume (FEV1) &gt; or
             equal 50% of predicted normal and a post-bronchodilator FEV1 / Forced Vital Capacity
             (FVC) &lt; 70%.

          -  Current or ex-smokers with a smoking history of more than 10 pack-years

          -  Body mass index (BMI) between 18 and 33 kg/m2

          -  Written informed consent to participate in the study after receiving adequate previous
             information and prior to any study specific procedures

        Exclusion Criteria:

          -  Significant disease other than COPD as bronchial asthma, cystic fibrosis or clinically
             evident bronchiectasis

          -  Total blood eosinophil count &gt;/=600/mm3.

          -  Thoracotomy with pulmonary resection

          -  Regular use of daytime oxygen therapy

          -  Completion of a pulmonary rehabilitation program in the six weeks prior to the
             pre-study examination or current participation in a rehabilitation program

          -  Hypersensitivity to the investigational drug or to other quinolones and/or to inactive
             constituents of the inhalation powder

          -  Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline
             solution

          -  Acute pulmonary exacerbation

          -  Patients with a history of severe allergies, non-allergic drug reactions, or multiple
             drug allergies

          -  Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy
             with fluoroquinolones

          -  Oral beta-adrenergics, beta blockers

          -  Long acting anti-cholinergics within 2 weeks prior to pre-study examination

          -  Inhaled or oral steroids

          -  Methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout of
             long-acting theophylline prior to pre-study examination

          -  Antihistamines, antileukotrienes prescribed for asthma

          -  oral cromolyn sodium or oral nedocromil sodium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Pharmacology</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Inhalation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

